Search for: "Rachel Sachs" Results 121 - 140 of 156
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
Molnupiravir may become the first COVID-19 pill. What took so long?
5 Nov 2021, 8:20 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Regulatory Responses to N95 Respirator Shortages
21 Apr 2020, 2:09 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOur recent posts have highlighted shortages in three COVID-19-related knowledge goods: testing, drugs (such as those needed to put patients on ventilators), and clinical trial information about effective treatments. [read post]
Written Description - http://writtendescription.blogspot.com/
Structural Racism and COVID-19
11 Jun 2020, 2:30 pm by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How will the FDA’s new COVID-19 vaccine guidance affect development efforts?
10 Jul 2020, 8:59 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How are COVID-19 vaccine manufacturers aiming to encourage trust in the FDA’s approval process?
2 Oct 2020, 7:10 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How can policymakers encourage the expansion of at-home diagnostic testing for COVID-19?
2 Jun 2020, 10:31 pm by Lisa Larrimore Ouellette
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How will the FDA’s new COVID-19 vaccine guidance affect development efforts?
10 Jul 2020, 8:59 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How can innovation and regulatory policy accomplish robust COVID-19 testing?
15 Apr 2020, 8:14 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowIt’s now clear that expansive, population-wide testing is part-and-parcel of every successful COVID-19 containment strategy. [read post]
Written Description - http://writtendescription.blogspot.com/
How can policymakers encourage the expansion of at-home diagnostic testing for COVID-19?
2 Jun 2020, 10:31 pm by Lisa Larrimore Ouellette
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How can health regulators maintain public trust when facing scientific uncertainty?
24 Jun 2020, 5:36 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How are COVID-19 vaccine developers and regulators responding to variants?
25 Mar 2021, 1:24 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What’s happening with proposals for a WTO waiver of COVID-related IP?
30 Jul 2021, 5:03 am by Lisa Larrimore Ouellette
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What can policymakers learn from the disastrously slow COVID-19 vaccine rollout?
12 Jan 2021, 9:04 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What are the challenges in developing information around mixing-and-matching COVID-19 vaccines and therapies?
21 Jan 2022, 8:35 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Remdesivir Part I: Incentivizing Antiviral Innovation
12 May 2020, 7:49 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How can innovation and regulatory policy accomplish robust COVID-19 testing?
15 Apr 2020, 8:14 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowIt’s now clear that expansive, population-wide testing is part-and-parcel of every successful COVID-19 containment strategy. [read post]
Written Description - http://writtendescription.blogspot.com/
Are COVID-19 vaccine advance purchases a form of vaccine nationalism, an effective spur to innovation, or something in between?
5 Aug 2020, 11:43 am by Lisa Larrimore Ouellette
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Regulatory Responses to N95 Respirator Shortages
21 Apr 2020, 2:09 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOur recent posts have highlighted shortages in three COVID-19-related knowledge goods: testing, drugs (such as those needed to put patients on ventilators), and clinical trial information about effective treatments. [read post]
Written Description - http://writtendescription.blogspot.com/
What can policymakers learn from the disastrously slow COVID-19 vaccine rollout?
12 Jan 2021, 9:04 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
Why is HHS blocking FDA from regulating some diagnostics, and how will this affect COVID-19 testing?
25 Aug 2020, 4:50 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/